Watchlist

Watchlist
AcelRx Pharmaceuticals, Inc. (ACRX)
AcelRx Pharmaceuticals, Inc. (ACRX)
After Hours Gainers / Losers
Top gainers: SD +6.3% . UEPS +3.5% . ENIC +3.3% . XNET +2.7% . VERI +2.3% . More news on: SandRidge Energy, Inc., Net 1 UEPS Technologies, Inc., Xunlei Limited, Stocks on the move, Read more …
FDA issues guidance on development of generic abuse-deterrent opioids
In a statement , FDA Commissioner Scott Gottlieb, M.D. says the agency is taking steps to help drug makers develop approvable generic opioid medications that incorporate abuse-deterrent characteristics. More news on: Teva Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Limited…
Cost of U.S. opioid epidemic tops $500B
In an analysis to be released today, the White House will say the true cost of the opioid drug epidemic in 2015 was $504B, more than six times larger than the most recent estimate. More news on: Johnson & Johnson, Endo International plc, Teva Pharmaceutical Industries Limited, Health…
Your Daily Pharma Scoop: A Look At Sanofi, Ultragenyx Gets FDA Nod, Capricor Tumbles
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Sanofi Today we will discuss an art…
AcelRx Pharmaceuticals Reports Publication of Manuscript Analyzing Sufentanil Sublingual Tablets in Patients with Postoperative Pain
REDWOOD CITY, Calif. , Nov. 16, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, reported the publication of a m…
Your Daily Pharma Scoop: Portola Ahead Of Catalysts, AstraZeneca Gets Two FDA Approvals, GW Pharmaceuticals' Price Target Lowered
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Portola Pharmaceuticals Today we will …
Premarket Losers as of 9:05 am
RELY -38% . More news on: Real Industry, Inc., Neovasc Inc., Infinity Pharmaceuticals, Inc., Stocks on the move, Read more …
AcelRx Pharmaceuticals' (ACRX) CEO Vince Angotti on Q3 2017 Results - Earnings Call Transcript
AcelRx Pharmaceuticals, Inc. (ACRX) Q3 2017 Earnings Conference Call November 09, 2017 04:30 PM ET Executives Jane Wright-Mitchell - Chief Legal Officer Vince Angotti - CEO Pam Palmer - Chief Medical Officer Raffi Asadorian - CFO Analysts Randall Stanicky - RBC Capital Ma…
AcelRx Pharmaceuticals misses by $0.01, misses on revenue
AcelRx Pharmaceuticals (NASDAQ: ACRX ): Q3 EPS of -$0.28 misses by $0.01 . Revenue of $1.49M (-55.8% Y/Y) misses by $0.73M . Press Release More news on: AcelRx Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,
AcelRx Pharmaceuticals Reports Third Quarter 2017 Financial Results
REDWOOD CITY, Calif. , Nov. 9, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company today reported third quarter 2017 financial results. "In response to the DSUVIA CRL, we are pleased to have compiled and submitted the Briefing B…
AcelRx Pharmaceuticals Reports Publication of Manuscript Evaluating Sufentanil Sublingual Tablets for Moderate-to-Severe Acute Pain in the Emergency Department
REDWOOD CITY, Calif. , Nov. 9, 2017 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, reported the publication of…
AcelRx Pharmaceuticals, Inc. (ACRX)